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AbstrAct
Intracellular Ca2+ levels are important regulators of cell cycle and proliferation. 
We, and others, have previously reported the role of KCa3.1 (KCNN4) channels 
in regulating the membrane potential and the Ca2+ entry in association with cell 
proliferation. However, the relevance of KC3.1 channels in cancer prognosis as 
well as the molecular mechanism of Ca2+ entry triggered by their activation remain 
undetermined. Here, we show that RNAi-mediated knockdown of KCa3.1 and/or 
TRPC1 leads to a significant decrease in cell proliferation due to cell cycle arrest in 
the G1 phase. These results are consistent with the observed upregulation of both 
channels in synchronized cells at the end of G1 phase. Additionally, knockdown of 
TRPC1 suppressed the Ca2+ entry induced by 1-EBIO-mediated KCa3.1 activation, 
suggesting a functional cooperation between TRPC1 and KCa3.1 in the regulation of 
Ca2+ entry, possibly within lipid raft microdomains where these two channels seem to 
co-localize. We also show significant correlations between KCa3.1 mRNA expression 
and poor patient prognosis and unfavorable clinical breast cancer parameters by 
mining large datasets in the public domain. Together, these results highlight the 
importance of KCa3.1 in regulating the proliferative mechanisms in breast cancer cells 
as well as in providing a promising novel target in prognosis and therapy.
IntroductIon
Breast cancer is one of the most frequent 
malignancies in women worldwide. There have been 
striking advances in breast cancer therapy over the last 
decade. However, patients with advanced disease typically 
respond poorly and many still die of the complexity of 
refractory breast cancers. Understanding the regulatory 
mechanisms that influence cancer cell growth and survival 
is the key to developing new targeted therapies and more 
efficacious pharmacological approaches. Ion channels of 
the K+ and TRP (Transient Receptor Potential) channel 
families are very important players in the regulation of 
specific stages of cancer progression, and are increasingly 
studied as promising targets for novel molecular cancer 
therapies [1–10]. 
Among the K+ channels, the intermediate-
conductance Ca2+-activated K+ channels (KCa3.1, 
gene name KCNN4) have been widely studied in many 
cancers. Indeed, Jäger and collaborators have reported 
6-66 fold increase of KCa3.1 mRNA levels in 89% of 
the tested primary pancreatic tumor tissues as compared 
to non-tumor tissues [11]. Similar results were found in 
prostate cancer [12] as well as in endometrial cancer, 
where KCa3.1 showed expression levels that were higher 
in tumor than in normal tissues, but that were also higher 
in cancer than in atypical hyperplasia [13]. KCa3.1 
expression level has also been correlated with breast 
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tumor grade. These findings suggest that KCa3.1 channels 
are important for cancer cell proliferation, and that their 
blockade might prove useful as therapy in patients with 
up-regulated KCa3.1 tumor expression. In this context, 
we have previously investigated the role and functional 
expression of KCa3.1 channels in controlling breast cancer 
cell cycle progression [14]. We have shown that KCa3.1 
channels are involved in cell proliferation by regulating 
G1/S transition. Both KCa3.1 mRNA expression and 
channel activity increased during G1 phase progression, 
concomitant with increased Ca2+ entry. Nevertheless, the 
molecular mechanisms involved in this Ca2+ entry remain 
unknown. 
Over the past few years, many studies have 
investigated the expression of Ca2+ channels in breast 
cancer cell lines in order to elucidate their involvement 
in regulating Ca2+ entry. Some of these studies have 
reported that TRPC1, TRPC6 and TRPM7, members of 
TRP channel family, are involved in cell proliferation as 
well as in regulating Ca2+ entry in breast cancer [15–18]. 
We also showed that TRPC1 mRNA and protein levels 
were higher in breast ductal adenocarcinoma tissues 
than in adjacent non-tumor tissues [3]. Consistent with a 
causal role of TRPC1 in breast cancer, Mandavill et al., 
showed that TRPC1 expression increased in infiltrating 
ductal carcinoma samples with microcalcifications when 
compared with age-matched controls without calcification 
or cancer [19]. 
The present study aims to investigate the 
mechanisms by which KCa3.1 regulates Ca2+ entry leading 
to breast cancer cell proliferation. We show, for the first 
time, a strong endogenous interaction between KCa3.1 
and TRPC1 channels and a potential co-localization 
in lipid rafts. This co-localization allows TRPC1 
channels to control the Ca2+ entry mediated by KCa3.1 
activation, triggering signaling pathways that promote 
cell proliferation. In addition, this study presents the 
first analyses of KCa3.1 expression in patient prognosis 
and other important clinical correlations in breast cancer 
datasets in the public domain. These strongly suggest 
that KCa3.1 is involved in breast cancer proliferation, 
making it a promising target for the development of novel 
therapies. 
results
both trPc1 and Kca3.1 are involved in McF-7 
cell proliferation
We have previously reported that hyperpolarization 
induced by KCa3.1 activation is a key element for cell 
cycle progression in MCF-7 breast cancer cells [14]. 
We have also demonstrated that MCF-7 cell proliferation 
can be dependent on Ca2+ entry through TRPC1 channels 
[15, 16]. Here we investigate whether KCa3.1 and TRPC1 
use a common pathway in controlling cell growth. We 
first tested the efficacy of siRNA-KCa3.1 (siKCa3.1) 
and siRNA-TRPC1 (siTRPC1), used individually or in 
combination. As shown in Figure 1, 72 h treatment with 
siTRPC1 and siKCa3.1 significantly reduced the mRNA 
expression level of TRPC1 (64.9 ± 0.9 % decrease, 
p = 7.37 • 10-7) and KCa3.1 (62.3 ± 2.6 % decrease, 
p = 2.17 • 10-5), respectively (n = 4, Figure 1A, 1B). The 
knockdown efficacy was also significant at the protein 
level (55% decrease for KCa3.1 and 77% decrease for 
TRPC1). Additionally, TRPC1 silencing did not affect 
the level of KCa3.1 expression and neither did KCa3.1 
silencing for TRPC1 expression level (Figure 1A–1D). 
Our results demonstrate that these two channels do not 
transcriptionally regulate each other. We then measured 
the effect of TRPC1 and KCa3.1 silencing on MCF-7 cell 
proliferation using a Trypan Blue assay. We found that 
the proliferation rate was significantly decreased in cells 
transfected with siTRPC1 (66.6 ± 4%; p = 0.005, n = 6) 
and siKCa3.1 (56.3 ± 5%; p = 0.003, n = 6) compared 
to siCTL (100 ± 4.2%). Interestingly, no additive or 
synergistic effects were observed in cells transfected 
with both siTRPC1 and siKCa3.1 compared to the 
effects obtained with siTRPC1 or siKCa3.1 (Figure 1E). 
Under all conditions, no significant cell mortality was 
detected.
To determine how siTRPC1 and siKCa3.1 affect 
cell proliferation, we performed cell cycle analysis 
using flow cytometry. Cell cycle distribution of MCF-7 
ells transfected with siCTL was 49.17 ± 1.5%, 35.67 
± 0.6 %, and 15.17 ± 1.06 %, in G0/G1, S and G2/M 
phases, respectively (Figure 2). An accumulation in G0/
G1 accompanied by a decrease in S phase was observed 
in cells transfected with siTRPC1 (66.93 ± 4.10 %, 17 
± 4.05 %, respectively, n = 3, p < 0.01). Similar results 
were obtained in MCF-7 transfected with siKCa3.1 
(67.9 ± 6.94 % in G0/G1 and 20 ± 5.65 % in S, n = 3, 
p < 0.01). Again, no additive effect was observed in 
cells transfected with both siTRPC1 and siKCa3.1 in 
comparison with cells transfected with siTRPC1 or 
siKCa3.1 alone (Figure 2, n = 3). Taken together, our 
results suggest that TRPC1 and KCa3.1 regulate cell cycle 
progression in G1 phase and G1/S transition most likely 
through a common pathway.
trPc1 and Kca3.1 are over-expressed in end 
G1 phase
Our previous study has shown an increase of KCa3.1 
mRNA in the end of G1 phase and during S phase [14]. 
However, changes in TRPC1 expression level during the 
cell cycle progression of breast cancer cells have never 
been reported. Given the fact that TRPC1 is also involved 
in MCF-7 cell proliferation and its knockdown induces 
accumulation of cells in G1 phase (Figures 1 and 2), we 
analyzed its expression in cells synchronized in early or 
late G1 (phase). Using quantitative reverse transcriptase 
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Figure 1: trPc1 and Kca3.1 involvement in breast cancer cell proliferation. (A) qRT-PCR analysis of KCa3.1 mRNA 
expression in MCF-7 cells transfected with scrambled siRNA (siCTL), siRNA directed against KCa3.1 (siKCa3.1), siRNA directed against 
TRPC1 (siTRPC1). The graph shows KCa3.1 mRNA expression normalized to β-actin mRNA expression (n = 4). (b) qRT-PCR analysis 
of TRPC1 expression level in MCF-7 cells transfected with siCTL, siKCa3.1 or siTRPC1. The graph shows TRPC1 mRNA expression 
normalized to b-actin mRNA expression (n = 4). (c) Representative western blot showing the effect of siRNAs directed against KCa3.1 and 
TRPC1 on the protein level of KCa3.1. (d) Representative western blot showing the effect of siRNAs directed against KCa3.1 and TRPC1 
on the protein level of TRPC1. (e) Analysis of MCF-7 cell proliferation transfected with siCTL, siKCa3.1, siTRPC1 or both siKCa3.1 
and siTRPC1. Cell proliferation is measured 72 h post-transfection. Values are reported as mean ± SEM normalized to the control (n = 4). 
**p < 0.01, *** p < 0.001, n.s.: not significant.
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PCR (qRT-PCR), we confirm that KCa3.1 mRNA level 
increases in end G1 phase compared to early G1 phase 
(Figure 3A, p < 0.001, n = 4). Additionally, we found 
that, like KCa3.1, TRPC1 expression increased in end 
G1 to reach 2.51-fold the level of expression in early G1 
phase (Figure 3B, p < 0.001, n = 4). This upregulation 
was also reflected by an increase of protein expression 
(Figure 3C, 3D). Our results demonstrate that both TRPC1 
and KCa3.1 are transcriptionally upregulated during the 
cell cycle progression supporting their role in the G1 phase 
and cell proliferation. 
Kca3.1 activation induces ca2+ entry through 
trPc1 channel
Previous reports have demonstrated TRPC1 as a key 
player in both constitutive Ca2+ entry and Store Operated 
Calcium Entry (SOCE) [20–23] as well as in MCF-7 cell 
proliferation through ERK1/2 pathways [16]. We also have 
reported that KCa3.1 regulates Ca2+ influx by regulating 
the resting membrane potential (RMP) in the MCF-7 cell 
line [14]. Indeed, silencing KCa3.1 generates a strong 
depolarization of the RMP [24]. To further understand the 
relationship between TRPC1 and KCa3.1 in regulating 
BC cell proliferation, we investigated the involvement of 
TRPC1 in both basal and KCa3.1-regulated Ca2+ influx. 
The basal Ca2+ influx was measured indirectly using 
Mn2+ dye-quenching method where quenching of fura-2 
fluorescence is induced by adding external manganese. 
In order to keep the channels active under the 
physiological conditions, cells were loaded with fura-2 
in the presence of their growth medium. The culture 
medium was only washed out right before the calcium 
measurement. This step was critical to record the full basal 
activity, since removal of serum significantly decreased 
the quenching slope (Figure 4A, 4B). This time-dependent 
effect of the washout would be the result of ion channels 
deactivation due to the removal of all stimuli. As it is well 
established that serum contains growth factors that trigger 
store-operated calcium entry and calcium oscillations, 
hence activating any store-operated calcium channels and 
calcium-activated channels. After establishing the optimal 
recording conditions, we then measured the contribution 
of TRPC1 and KCa3.1 to the basal calcium influx. As 
Figure 2: silencing of trPc1 and Kca3.1 expression induces accumulation of cells in G1 phase. MCF-7 cells were 
transfected using Amaxa with either control siRNA (siCTL), KCa3.1 siRNA (siKCa3.1), TRPC1 siRNA (siTRPC1) or both TRPC1/KCa3.1 
siRNAs (siTRPC1/siKCa3.1), and then cultured in EMEM medium with 5% FBS for 72 h. After staining with propidium iodide, cell cycle 
distribution (G0/G1, S and G2/M phases) was examined by flow cytometry. The graph represents the percentage of cells in different phases 
under control condition or KCa3.1 or TRPC1 knockdown conditions (n = 3). Insets show raw data from the FACS acquisition software. 
Values are reported as mean ± SEM. **, p < 0.01, n.s.: not significant.
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illustrated in Figure 4 (Figure 4C, 4D) TRPC1 silencing 
decreased the dye-quenching slope by 38.25 % vs. control 
(p = 7.47 • 10−9, Figure 4C, 4D). Using the same approach 
described above, we investigated the importance of the 
depolarization induced by KCa3.1 knockdown on the Ca2+ 
influx. Transfected cells with siKCa3.1 showed a stronger 
reduction of the quenching slope (thus Ca2+ influx) in 
comparison with the control (63.39 %, p = 3.23 • 10−16, 
Figure 4C, 4D). The simultaneous knockdown of both 
TRPC1 and KCa3.1 resulted in a similar effect (60.31 %, 
p = 3.13 • 10−13, Figure 4C, 4D). Taken together, our 
results showed that both TRPC1 and KCa3.1 regulate 
basal Ca2+ entry in MCF-7 cells. Additionally, combining 
the two siRNA did not result in an additive or synergistic 
effect, suggesting the presence of a functional cooperation 
between TRPC1 and KCa3.1. 
To confirm our hypothesis, we studied the effect 
of pharmacological activation of KCa3.1 on the basal 
Ca2+ influx in cells transfected with siTRPC1 and/or 
siKCa3.1. As mentioned above, we know that KCa3.1 
channels regulate the membrane potential. Thus, their 
activation will hyperpolarize the plasma membrane and 
consequently enhance the driving force for Ca2+. These 
effects are illustrated in Figure 5 where we can see 
that in the control cells, the extracellular perfusion of 
200 µM 1-EBIO induced a significant increase in the basal 
Ca2+ influx while in siKCa3.1-tranfected cells, 1-EBIO 
effect was reduced by 78.94% vs. control (p = 9.4 • 10−13, 
Figure 5A). We then investigated the involvement of 
TRPC1 channels in the Ca2+ entry induced by 1-EBIO-
mediated KCa3.1 activation. Knockdown of TRPC1 
showed a strong reduction in the magnitude of 1-EBIO 
response (75.97 %, p = 9.66 • 10−9, Figure 5A). Again, 
the simultaneous knockdown of TRPC1 and KCa3.1 did 
not result in a significant additive effect (83.96% decrease 
vs. Ctrl with p = 3.82 • 10−8, p = 0.6 vs. siTRPC1 and 
p = 0.74 vs. siKCa3.1). Taken together, our results suggest 
that the hyperpolarization-evoked Ca2+ entry, due to 
KCa3.1 activation, is mediated by the TRPC1 channels, 
and hence supporting our hypothesis of the functional 
coupling between KCa3.1 and TRPC1. 
trPc1 and Kca3.1 appear co-localized in lipid 
rafts
To test the hypothesis of whether the observed 
functional coupling is due to protein-protein 
interaction between TRPC1 and KCa3.1, we conducted 
immunoprecipitation experiments using a specific KCa3.1 
antibody. Total MCF-7 protein lysate was utilized to 
Figure 3: trPc1 and Kca3.1 upregulation during G1 phase progression. (A) qRT-PCR analysis of KCa3.1 mRNA expression 
level in synchronized cells. (b) qRT-PCR analysis of TRPC1 mRNA expression level in synchronized cells. (c) Representative western 
blot showing the expression level of KCa3.1 in synchronized cells. (d) Representative western blot showing the expression level of 
TRPC1 in synchronized cells. Cell synchronization was achieved by 24 h treatment of cells by either serum- and phenol red-free medium 
(mid-G1) or by complete medium supplemented with 2 mM thymidine (end-G1). Values are reported as mean ± SEM normalized to control. 
***p < 0.001.
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immunoprecipitate KCa3.1, after which the precipitate 
was used for immediate western blot and probed with 
antibodies directed against TRPC1 and KCa3.1. As shown 
in Figure 6, KCa3.1 precipitate exhibited a pull-down 
of TRPC1 suggesting a co-localization and interaction 
between the two channels (Figure 6A). 
Various ion channels localize to cholesterol and 
sphingolipid-enriched regions of the plasma membrane 
known as lipid microdomains or lipid rafts and increasing 
evidence suggests that membrane rafts regulate channel 
function in a number of different ways, including 
selectively recruiting interacting signalling molecules 
to generate subcellular compartments that may be 
important for efficient and selective signal transduction 
[25–27]. We then set out to examine the co-localization 
of KCa3.1 and TRPC1 channels in the plasma membrane 
microdomains. For this purpose, we experimentally 
disrupted the lipid rafts by pretreatment of MCF-7 cells 
with methyl-β-cyclodextrin (MβCD), the most commonly 
used cyclodextrin for cholesterol depletion and hence lipid 
raft disruption [28–30]. MCF-7 cells were treated with 
5 mg/ml MβCD for 24 h at 37°C prior to collecting the cell 
lysates and performing immunoprecipitation. We found 
that the treatment with MβCD resulted in a 52.8% decrease 
of the pulled-down amount of TRPC1 (Figure 6A, 6B). 
Taken together, our results demonstrate that TRPC1 and 
KCa3.1 are at least partially co-localized in lipid rafts 
where they interact and cooperate in regulating Ca2+ entry 
in MCF-7 cells.
Figure 4: trPc1 and Kca3.1 channels regulate the basal ca2+ entry. (A) Representative traces of Mn2+ quenching in cells at 
different time points after washing out the culture medium. (b) The graph represents the average slope value of 9 measurements for each 
condition. ***p < 0.001. (c) Representative traces of Mn2+ quenching in cells transfected with siCTL, siKCa3.1, or siTRPC1). Slope values 
are: −6.73 ± 0.14, for siCTL, −2.46 ± 0.13 for siKCa3.1, −4.15 ± 0.23 for siTRPC1 and −2.67 ± 0.22 for co-transfection of siKCa3.1 and 
siTRPC1. (d) The graph represents the average slope value of 31 measurements for each condition. *** p < 0.001.
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High Kca3.1 mrnA expression correlates to 
unfavorable clinical parameters and poor patient 
prognosis in breast cancer 
The previous results clearly show the importance 
of KCa3.1 and TRPC1 function for MCF-7 breast cancer 
cell proliferation. Both KCa3.1 [11, 13, 21] and TRPC1 
[12, 13] have separately been described as involved in 
breast cancer cell proliferation. In addition, both KCa3.1 
and TRPC1 mRNA and protein levels were shown to be 
higher in breast cancer tissue than in matched normal 
breast tissue [3, 10]. However, to our knowledge no data 
have been published on a possible prognostic function for 
these two genes. Also, no public knowledge exists on a 
role in the various molecular subtypes for breast cancer, 
or on the molecular mechanisms by which KCa3.1 and 
TRPC1 could be involved in breast cancer progression. 
We therefore decided to perform data mining 
on genome-wide mRNA expression profiles of breast 
cancer sample sets in the public domain. We were able to 
download and analyze 17 breast cancer datasets on three 
different array platforms (Table 1). No clear pattern for 
TRPC1 mRNA expression emerged. Instead, it seemed 
to be widely expressed in all breast cancer sets and 
subtypes (data not shown). However, KCa3.1 showed 
very distinctive behavior. In 12 of 13 datasets that were 
annotated for SBR/Elston-Ellis tumor grade, KCa3.1 
showed a significantly higher expression in the highest 
tumor grade (grade 3). Also, it was significantly better 
expressed in ER-negative than in ER-positive samples 
(in 15 of 16 annotated datasets), and in PR-negative versus 
PR-positive samples (in 10 of 11 annotated datasets). 
Conflicting correlation patterns were not observed in 
any of the datasets. In sharp contrast, KCa3.1 expression 
never showed a correlation to HER2/Neu/ERBB2 over-
expression. When KCa3.1 mRNA expression was 
examined between the different molecular breast cancer 
subtypes [31], it was significantly highest expressed in the 
aggressive basal-like subtype in all 6 datasets annotated 
for this parameter (Figure 7) [31–33]. In addition, five 
datasets contained information on the mutation status of 
the P53 tumor suppressor gene. In all 5, KCa3.1 mRNA 
expression was significantly higher in tumors with, 
than in tumors without P53 gene mutations. The results 
clearly show that KCa3.1 mRNA expression is higher 
in tumors with unfavorable (ER-negative, PR-negative, 
P53-mutated, basal-like) than in tumors with favorable 
(ER-positive, PR-positive, P53 wildtype, luminal/normal-
like) clinical parameters. The expression patterns were 
consistent over almost all 17 datasets, which had very 
different tumor subtype and grade compositions, contained 
patients from diverse geographical regions, and were 
analyzed on four separate array platforms. We therefore 
propose that these results are very robust. The correlation 
of KCa3.1 expression and P53 mutant status in addition 
offers a possible mechanism for increased proliferation in 
cells with high KCa3.1 activity. 
The ER/PR, P53, and subtype status of tumors 
with high KCa3.1 expression suggest that KCa3.1 is 
correlated to rapid tumor growth and spread, and poor 
patient outcome. To establish the prognostic value for 
KCa3.1 tumor expression, we analyzed all four public 
breast cancer datasets that had survival data. Indeed, in 
Kaplan-Meier graphs, high KCa3.1 tumor expression 
was significantly prognostic for poor outcome in two 
datasets (Figure 8). Interestingly, KCa3.1 expression was 
Figure 5: trPc1 involvement in ca2+ entry induced by Kca3.1 activation. (A) Representative traces of 1-EBIO-induced Ca2+ 
entry. 1-EBIO was used at 200 µM. (b) Quantitative analysis of 1-EBIO-induced Ca2+ entry. The increase of [Ca2+]i induced by KCa3.1 
activation is drastically reduced by siKCa3.1 and siTRPC1. ***p < 0.001.
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prognostic in patients that had a long average survival (in 
the Booser-508 dataset, panel A), as well as in primary 
tumors of patients that were known to later relapse and 
therefore had only short average survival (in the Smid-
210 dataset, panel B). In the two other datasets with 
survival data, Bergh-159 and Bertucci-266, the correlation 
between high KCa3.1 tumor mRNA expression and poor 
outcome showed similar trends, but these did not reach 
statistical significance (not shown). The observation that 
KCa3.1 is a prognostic marker in breast cancer is therefore 
preliminary, and awaits the analysis of more public data 
when they become available.
Together, these data strongly suggest that KCa3.1 
has an important role in the breast cancer cell, in particular 
in tumors that are not amenable to standard (hormone) 
treatment, and that have accumulated DNA repair defects. 
This strengthens the case for KCa3.1 as a potential 
target for novel drug development and warrants further 
investigation in different breast cancer subtypes.
dIscussIon 
The major findings of this study are 1. KCa3.1 
channel is a key regulator of breast cancer cell cycle 
progression and proliferation and its high mRNA 
expression in breast cancer patients is associated with 
unfavorable clinical parameters and poor prognosis, 
which makes this channel an attractive target for 
developing new therapy, and 2. KCa3.1 regulates Ca2+ 
influx and cell proliferation by functional cooperation 
with TRPC1 channel in our MCF-7 cell model. The 
expression of both channels increases at the end of G1 
phase and silencing either KCa3.1 or TRPC1 reduces cell 
proliferation, accumulates cells in G1 phase, and reduces 
both basal Ca2+ entry and Ca2+ entry activated by 1-EBIO 
(KCa3.1 activator). Additionally, co-immunoprecipitation 
experiments showed that TRPC1 and KCa3.1 are, at least 
partially, colocalized in the plasma membrane, likely in 
the lipid rafts where they may cooperate to regulate Ca2+ 
entry and thus G1 phase progression and cell proliferation. 
KCa3.1 channel expression has been shown to 
be upregulated in many cancers, where it promoted 
cell growth and cell cycle progression [11, 13, 34, 35]. 
Several studies have shown that the activity of KCa3.1 
channels facilitates the Ca2+ influx by hyperpolarizing the 
cell membrane and increasing the driving force for Ca2+ 
influx in different cell types [36–38]. In breast cancer 
MCF-7 cells, our previous work has demonstrated that 
when cells progress through G1 phase, they show an 
increase of KCa3.1 expression level and current density 
paralleled by a highly negative resting membrane potential 
(RMP) and a higher basal Ca2+ concentration [Ca2+]i [14]. 
Pharmacological inhibition of KCa3.1 channels reduces 
the concentration of intracellular Ca2+ and depolarizes the 
RMP in cells accumulated at the end of G1 phase [39]. We 
have also showed that the decrease of the extracellular Ca2+ 
concentration [Ca2+]o inhibits MCF-7 cell proliferation 
suggesting that Ca2+ influx is essential for BC MCF-7 cell 
proliferation [40]. TRPC1 is an important Ca2+ regulator 
in a variety of cell types including malignant gliomas 
[41], ovarian cancer [42], and lung cancer [43,44]. 
In the MCF-7 breast cancer cell line, we previously 
demonstrated that TRPC1 provides a Ca2+ entry that 
regulates cell proliferation via ERK1/2 phosphorylation 
[16]. Here, we show that silencing of TRPC1 induced 
G0/G1 cell cycle arrest resulting in a significant decrease 
Figure 6: trPc1 and Kca3.1 appear co-localized in lipid rafts in McF-7 cells. (A) MCF-7 cell lysates were subjected to 
immunoprecipitation with anti-KCa3.1. KCa3.1 and TRPC1 were identified by Western blot analysis using anti-KCa3.1 and anti-TRPC1 
antibodies. Cells were treated or not treated with methyl-β-cyclodextrin. (b) Quantification of the KCa3.1 and TRPC1 interaction in MCF-7 
cells treated or not treated with methyl-β-cyclodextrin. *** p < 0.001.
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table 1: Kca3.1 expression correlations in public breast cancer datasets
dataset Kca3.1 Grade er status erbb2 status Pr status P53 status subtype Platform Gse PMId
name size mrnA P value P value P value P value
Bergh 159 113.9 (66) Highest in 3b Highest in Basale
Affymetrix 
U133A 1456 16280042
Bertucci 266 170.4 (217) Highest in 3 3.2 • 10−19 Not 
significant
2.0 • 10−16 2.2 • 10−4
Highest in 
Basal
Affymetrix 
U133P2 21653 20490655
Black 107 157.3 (81) Highest in 3 4.0 • 10−6 8.5 • 10−7 Affymetrix U133P2 36771 22564725
Booser 508 182.8 (180) Highest in 3 5.2 • 10−25 Not 
significant
1.9 • 10−13
Highest in 
Basal
Affymetrix 
U133A 25066 21558518
Chin 124 121.4 (64) Highest in 3c 1.7 • 10−9 Not 
significant
1.1 • 10−5 1.1 • 10−3
Highest in 
Basal
Affymetrix 
U133A g 17157792
Clynes 121 201.1 (35) Highest in 3c 5.7 • 10−4 Affymetrix U133P2 42568 23740839
EXPO 351 125.9 (188) Highest in 3b 5.0 • 10−8 Not 
significant
8.7 • 10−3
Affymetrix 
U133P2 2109 i
Halfwerk 947 n.d.a Highest in 3 1.3 • 10−19 Not 
significant
7.3 • 10−14 1.4 • 10−10
Affymetrix 
U133A h i
Iglehart 123 196.4 (103) Highest in 3 4.7 • 10−10 Not 
significant
Affymetrix 
U133P2 5460 18297396
Jonsdottir 94 198.3 (54) Highest in 3 4.6 • 10−6 Not 
significant
Illumina 
hwg6v3 46563 24599057
Miller 251 120.4 (108) Highest in 3 3.1 • 10−5 1.9 • 10−4 1.4 • 10−9 Affymetrix U133A 3494 16141321
Prat 156 144.7 (76) Trend onlyd Not 
significant
Trend 
onlyd
Affymetrix 
U133P2 50948 24443618
Servant 343 204.3 (271) Highest in 3 3.3 • 10−21 Not 
significant
3.3 • 10−6 6.7 • 10−5
Highest in 
Basalf
Illumina 
hwg6v3 30682 22271875
Sotiriou 198 94.4 (112) Trend only 1.7 • 10−4 Affymetrix U133A 7390 17545524
TCGA 528 n.d.a 4.6 • 10−34 Not 
significant
3.4 • 10−20
Agilent 
244 K j 23000897
Wang 286 138.6 (169) 2.2 • 10−17 Affymetrix U133A 2034 15721472
Wessels 178 115.6 (178) 1.9 • 10−11 0.02 Highest in Basale
Illumina 
hwg6v3 34138 23203637
All 26 breast cancer mRNA expression profiling datasets in the public domain were scrutinized for KCa3.1 
(KCNN4 gene) mRNA expression and clinical parameters. 17 datasets were subsequently analyzed using R2. 
Five datasets with a sample size < 80 (Concha-66 (GSE29431), Desmedt-55 (GSE16391), Loi-77 (GSE9195), 
Quiles-61 (GSE28844), and Wessels-60 (GSE41656)) and four datasets with missing clinical parameters 
(Bos-204 (GSE12276), Miller-116 (GSE5462), Sotiriou-120 (GSE16446), and Zhang-136 (GSE12093), were omitted from 
analysis Data were downloaded and analyzed as described in the Materials and Methods. The first two columns represent name 
and size of the dataset. KCNN4 describes the average present KCa3.1 mRNA expression values in the datasets, with between 
brackets the amount of samples in the dataset that show significant expression. Grade represents the KCa3.1 expression in the 
three grades (1–3) according to Elston-Ellis/SBR [63]. ER, ERBB2 (Her2/Neu), and PR status describe the KCa3.1 expression 
in receptor-negative versus receptor-positive samples; the P values denote significantly higher expression in receptor negative 
samples. P53 status describes the KCa3.1 expression in tumours with versus tumours without P53 gene aberrations; positive 
P values denote significantly higher expression in tumours with P53 aberrations. Subtypes describe KCa3.1 expression in the 
five breast cancer molecular subgroups (basal-like, ERBB2-overexpressing, luminal-a, luminal-b, and normal-like) according 
to [31].  Platform lists the kind of arrays used, GSE shows the NCBI GEO set number, and PMID the PubMed ID of the array 
publication.
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of cell proliferation. The fact that TRPC1 and KCa3.1 
knockdown similarly affected cell proliferation and cell 
cycle distribution strongly favored the hypothesis that 
TRPC1 channels may be the key actors in Ca2+ influx 
induced by KCa3.1 activation. This was confirmed by 
Mn2+ quenching, where silencing either TRPC1 or KCa3.1 
markedly decreased Ca2+ entry in our culture condition. 
Moreover, when TRPC1 was downregulated, the 
amount of Ca2+ entry in response to the KCa3.1 activator 
(1-EBIO) has significantly decreased suggesting that 
TRPC1 channels contribute to the Ca2+ entry induced by 
KCa3.1 channels activation (thus RMP hyperpolarization). 
KCa3.1 channels control G1 (mainly late G1) 
phase, G1/S transition, and G2/M phase in several types 
of cancer including breast, prostate, endometrial and colon 
[12, 13, 35, 45]. In breast cancer, the activation of KCa3.1 
contributes to the progression of cell through G1, and to 
G1/S transition [39]. TRPC1 has been also reported to play 
an essential role in cell cycle progression especially in G1 
phase [44, 46]. Indeed, an upregulation of TRPC1 protein 
level in the G1 compared with G0 was observed in Ehrlich 
Lettré Ascites (ELA) cells [46] while TRPC1silencing in 
non-small cell lung carcinoma cell lines decreased cyclin 
D1 and D3 expression levels, resulting in G0/G1 cell cycle 
arrest [44]. Here, we show that both TRPC1 and KCa3.1 
expression is increased at the end of G1 (Figure 3). 
Our results highlight a common pathway or a signaling 
connection between KCa3.1 and TRPC1 in the regulation 
of G1/S transition. 
Several studies have reported a physical interaction 
between Ca2+-activated K+ (KCa) channels with several 
Ca2+ partners including TRP channels [12,47–50]. For 
example, in vascular smooth muscle cells, TRPC1 
is physically associated with BKCa and Ca
2+ influx 
through TRPC1 activates BKCa to induce membrane 
hyperpolarization [49]. A similar interaction was proposed 
between KCa3.1 channels and store-operated calcium 
channels in macrophages. In this way, a small Ca2+ influx 
current induces a large KCa3.1 current providing the 
necessary electrochemical driving force for prolonged 
Ca2+ signaling and store repletion [51]. Furthermore, it has 
been shown that the TRPC1-mediated Ca2+ entry is the 
primary regulator of KCa3.1 channel in human salivary 
gland cells as it induces KCa3.1 channel activation 
leading to NFkB signaling and cell proliferation [52]. 
The TRPC1/KCa3.1 connection has been reported as an 
important Ca2+ signaling mechanism in the regulation of 
cancer cell migration [53, 54], but so far only one study 
has reported a link between KCa3.1 and TRP channels 
in cancer cell proliferation. Indeed, in the prostate 
cancer cell line LNCaP, TRPV6 has been proposed 
as a major source of passive Ca2+ influx in response to 
the hyperpolarization associated with KCa3.1 channels 
activation [12]. No specific interaction inhibitors exist 
that would allow to study the relationships between the 
physical and functional interactions of KCa and TRP 
channel proteins by disturbing the physical interactions. 
However, in the present study, we did find that KCa3.1 
physically associates with TRPC1, and is at least partially 
co-localized in the lipid rafts, suggesting that this close 
proximity allows TRPC1 channels to control the KCa3.1 
activation-mediated Ca2+ entry at least in part. We 
expressly note that in addition to the KCa3.1-TRPC1 
interaction, other Ca2+-regulating proteins are known to 
co-assemble with TRPC1, and might be involved in the 
Ca2+ signaling. These include other TRP channels, but also 
IP3, STIM1, and ORAI1. [22, 55, 56].
The results described above clearly show that the 
KCa3.1 expression and the KCa3.1/TRPC1 interaction 
are involved in proliferation of the MCF-7 breast cancer 
cell. In an effort to translate cell line experiment data to an 
in vivo patient situation, we analyzed KCa3.1 and TRPC1 
mRNA expression in public breast cancer patient sample 
sets. KCa3.1 and TRPC1 mRNA and protein levels have 
previously been shown to be higher in breast cancer than in 
matched normal tissue, but this was a single patient series 
without information on clinical and pathological breast 
cancer parameters or patient survival [3, 10]. Our mining 
of 17 public breast cancer datasets showed that KCa3.1 
tumor mRNA expression is significantly correlated to 
unfavorable breast cancer parameters: negative ER and 
PR status, P53 gene aberration, and the aggressive basal-
like molecular subtype. Indeed, a preliminary analysis for 
prognostic value of KCA3.1 tumor mRNA expression 
showed that in two of the four separate survival analyses 
available in the public domain, high KCa3.1 tumor mRNA 
aDataset expression values do not allow distinction between present and absent expression. b Expression is significantly higher 
in grade 3 versus grade 2, and in grade 2 versus grade 1, but only trends in grade 3 versus grade 1. c Expression is significantly 
higher in grade 3 versus grade 2, but only trends in the other comparisons. d In this dataset, the amounts of receptor-negative 
and receptor-positive samples are the opposite of the normal distribution, which could cause the non-significant comparison 
result. e The difference between basal-like and ERBB2-overexpressing trends, but is not significant. f This dataset does not 
contain “normal-like” samples. g E-TABM-158. h This dataset compiles the Chin-123 (also analyzed separately), Desmedt-147 
(GSE7390), Loi-178 (GSE6532), Miller-247 (GSE3494), Minn-96 (GSE5327), and Pawitan-156 (GSE1456) datasets. i This 
dataset has not yet been published. All comparisons were made using the Kruskal-Wallis test. j TCGA: http://tcga.cancer.gov/
dataportal.
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Figure 7: High Kca3.1 expression correlates with the basal breast cancer subtype. KCa3.1 tumor mRNA expression 
correlation with breast cancer molecular subtypes. Panels A-F represent the results from all 6 breast cancer datasets in the public domain 
that contain data on breast molecular subtypes: Bergh-159 (GSE1456), Bertucci-266 (GSE21653), Booser-508 (GSE25066), Chin-124 
(E-TABM-158), Servant-343 (GSE30682), and Wessels-178 (GSE34138), respectively. Below the graph are the different subtypes: basal-
like (basal), Her2/Neu/ERBB2 over-expressing (erbb2), luminal-a (luma), luminal-b (lumb) and normal-like (norm) according to [31], 
between brackets are the number of samples per subtype. Vertical bars represent the S.E.M. The Servant-343 set did not contain samples 
of the “normal” subtype. More data on the sets are in Table 1 and its legend. Statistical analysis was performed using the non-parametric 
Kruskal-Wallis test. * denotes significant differences with the basal subtype expression (all p < 0.005).
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expression was significantly prognostic for poor survival. 
These consistent results represent the most extensive 
KCa3.1 expression analysis in breast cancer so far. 
While the molecular mechanisms regulating KCa3.1 
and hormone receptor expression in breast cancer cells 
are yet unclear, the significant correlation between p53 
mutant status and high KCa3.1 expression we found fits 
well in the knowledge on KCa3.1 function and cell cycle. 
In MCF-7 cells, high KCa3.1 expression is found in (late) 
G1 and is essential for G1 to S transition. In contrast, 
KCa3.1 (or TRPC1) knockdown resulted in a G1 block. 
This block is most probably caused by P53, as KCa3.1 
knockdown has been shown to cause P53 activation, 
resulting in e.g. P21 accumulation in prostate cancer 
cells [12], and MCF-7 cells have wildtype P53 [57]. 
In aggressive breast cancer, the absence of functional P53 
would untether the effect of KCa3.1 on the cell cycle. 
The high KCa3.1 expression in especially those 
breast cancer subtypes that cannot be treated with existing 
hormone therapy and/or have poor outcome warrants 
further investigation. Testing of known or novel KCa3.1 
inhibitors, possibly in combination with classical DNA-
targeting drugs, might well unveil an essential role for 
KCa3.1 expression in breast cancer growth and survival, 
and yield a venue of treatment yet unavailable for patients 
suffering from aggressive, basal-like or triple-negative 
breast cancer. 
Figure 8: High Kca3.1 expression is prognostic for poor patient outcome in breast cancer. KCa3.1 expression correlation 
with survival: Kaplan–Meier graphs representing the survival prognosis of breast cancer patients based on high or low KCa3.1 tumor 
mRNA expression. (A) Kaplan-Meier analysis in the Booser-508 primary breast cancer dataset (censored at 84 months): upon dividing the 
patient group on average expression, those with high KCa3.1 tumor mRNA expression (n = 173) had a survival probability of 63%, while 
those with low KCa3.1 expression (n = 335) had a significantly higher survival probability of 75% (p = 3.9 · 10−5). Also when the patient 
group was divided on median KCa3.1 expression, the difference was significant (P = 7.6 ·10−4, not shown). (b) Kaplan-Meier analysis in 
the Smid-210 dataset of patients with known relapse (not censored): division of the patient group on average expression showed that the 
survival period of patients with low KCa3.1 tumor mRNA expression (n = 137) is significantly longer than that of patients with high KCa3.1 
expression (n = 58) (p = 9.5 · 10−3). Graphs are drawn up to 84 months. Patients at risk data during the analysis interval are not available 
for these datasets on the R2 website. The two other breast cancer datasets in the public domain that contain survival data (Bergh-159; 
GSE1456, and Bertucci-266; GSE21653) showed significant correlations between high KCa3.1 tumor mRNA expression and poor outcome 
in several different groupings, but these lost significance after Bonferoni correction for multiple testing (not shown).
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MAterIAls And MetHods
cell culture and cell synchronization
The MCF-7 breast cancer cell line was obtained from 
the American Type Culture Collection (LGC Standards, 
Molsheim, France). MCF-7 cells were grown in Eagle’s 
Minimum Essential Medium (EMEM; Gibco, Life 
Sciences, Cergy Pontoise, France) supplemented with 5% 
fetal bovine serum (FBS), 2 mM L-glutamine, and 50 µg/ml 
gentamicin (all from Gibco). The culture medium was 
changed every 2 days. Cells were maintained at 37°C in a 
humidified atmosphere with 5% CO2.
To obtain synchronized cell cultures accumulated in 
the early or late G1 phase, MCF-7 cells were cultured for 
24 h with serum- and phenol red-free EMEM [39, 58], or 
with complete EMEM medium supplemented with 2 mM 
thymidine [39], respectively.
cell transfection and rnA interference
Transfection of cells was performed using 
nucleofection technology (Amaxa Biosystems, Lonza, 
Aubergenville, France) according to the protocol 
as previously described [40]. Cells were transiently 
transfected with siRNA directed against TRPC1 and 
KCa3.1 [13, 16], or with scrambled siRNA as a control 
(siCTL) (siGENOME Non-Targeting siRNA, Dharmacon 
Research, Chicago, IL), and used 72 h after transfection.
cell proliferation assay
MCF-7 cells were grown in 35 mm Petri dishes in 
complete EMEM medium. The involvement of TRPC1 and 
KCa3.1 in cell proliferation was investigated on MCF-7 
cells transfected with siRNA as described above. Cell 
proliferation was determined by counting cells using a 
Trypan Blue assay. Mortality was scored by simultaneous 
counting of darkly stained cells (and never reached > 5% 
overall). The results were expressed as the percentage of 
proliferating cells in the experiment normalized to the 
control condition. 
cell cycle analysis
For the measurement of the cellular DNA content, 
cells transfected by siTRPC1 and siKCa3.1 or siCTL were 
pelleted, re-suspended in PBS/EDTA, treated with 20 µg/
ml of RNase A (Sigma-Aldrich, Lyon, France) and stained 
with 50 µg/ml of propidium iodide (Sigma-Aldrich). 
Samples were then analyzed using an Elite flow cytometer 
(Beckman Coulter, Villepinte, France). The percentage of 
cells in different phases was calculated using WinMDI 2.8 
(Purdue University, West Lafayette, Indiana) and Cylchred 
(Cardiff University, Cardiff, UK) software.
qrt-Pcr
Quantitative reverse transcriptase PCR (qRT-
PCR) was performed as previously described [16]. 
Sense and anti-sense PCR primers specific to KCa3.1 
(sense: GCAGGAACTGGCATTGGACT, anti-sense: 
CTGATCGTGCATTTAACCAGGA), TRPC1 (sense: 
GAGGTGATGGCGCTGAAGG, anti-sense: GCACGCC 
AGCAAGAAAAGC) and β-actin (sense: CAGAGCAA 
GAGAGGCATCCT, anti-sense: ACGTACATGGCTGGG 
GTG) were used. TRPC1 and KCa3.1 mRNA levels in 
breast cancer cells were normalized to the endogenous 
control (β-actin) using the Pfaffl method [59]:
Ratio = 
(Etarget)ΔCt target (siCTL – siTarget)
(Eref)ΔCt ref (siCTL – siTarget)
calcium imaging 
After transfection, cells were directly seeded 
on glass coverslips, and grown for an additional 72 h. 
Cells were then incubated in culture medium containing 
3 µM Fura-2 AM (Sigma Aldrich) for 45 minutes at 
37°C before Ca2+ measurement. After Fura loading, cells 
were washed and kept in extracellular saline solution 
containing 145 mM NaCl, 5 mM KCl, 2 mM CaCl2, 
1 mM MgCl2, 5 mM glucose 5, 10 mM HEPES-NaOH, 
at pH 7.4. The glass coverslip was mounted in a chamber 
on a Zeiss (Marly-le-Roi, France) microscope equipped 
for fluorescence. Fura-2 fluorescence was excited at 340 
and 380 nm using a monochromator (Polychrome IV; 
TILL Photonics, Planegg, Germany), and captured by a 
Cool SNAPHQ camera (Princeton Instruments, Evry, 
France) after filtration through a long-pass filter (510 nm). 
Metafluor software (version 7.1.7.0, Molecular Devices, 
St. Grégoire, France) was used for acquisition and 
analysis. The [Ca2+]
I
 concentration was derived from 
the ratio of the fluorescence intensities for each of the 
excitations wavelengths (F340/F380). All recording were 
made at room temperature. The cells were continuously 
perfused with the saline solution. The flow rate of the 
whole cell chamber perfusion system was set to 1ml/min 
and the chamber volume was 700 µl.
Manganese influx measurements
MCF-7 cells were plated on glass coverslips after 
transfection with siRNA-Control (siCTL) or siTRPC1 and 
siKCa3.1. To estimate divalent influx through the plasma 
membrane, we used the manganese-induced quenching of 
Fura2 approach as previously described [40]. Briefly, cells 
were loaded with 3 µM Fura-2 AM in the growth medium 
at 37°C for 45 min. After a period of 1 minute, the Ca2+ 
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(2 mM) present in the perfusion medium was replaced by 
2 mM Mn2+. To measure Mn2+ influx, cells were excited at 
360 nm and the emission signal was recorded at 510 nm at 
one second intervals. The Mn2+ influx was estimated from 
the quenching rate of 360 nm fluorescence.
co-immunoprecipation
MCF-7 cells were lysed in RIPA buffer (1% 
Triton X-100, 1% sodium deoxycholate, 150 mM NaCl, 
50 mM Tris-HCl pH 7.4, 2 mM EDTA, 0.5 mM sodium 
orthovanadate, and P8340 inhibitor cocktail (Sigma-
Aldrich)). 1 mg of MCF-7 protein lysates were precleared 
for 30 min with proteins A and G sepharose magnetic 
beads and then incubated over night with 3 µg of anti-
KCa3.1 antibody (sc-32949, Santa Cruz, Santa Cruz, CA). 
The antigen-antibody complexes were precipitated with 
proteins A and G sepharose magnetic beads (Millipore, 
PureProteome™ Magnetic Beads) for one hour. After 
denaturation, proteins were separated by denaturing SDS–
PAGE and transferred onto nitrocellulose membranes. 
KCa3.1 was detected using anti-KCa3.1 antibody 
(sc-32949, Santa Cruz, at 1:500) and anti-rabbit secondary 
antibody (TrueBlot Anti-Rabbit IgG HRP 18-8816, 
eBioscience, Paris, France, at 1:1000). Anti-TRPC1 anti-
body (ACC-010, Alomone, Jeruzalem, Israel, at 1:200) 
was used for TRPC1 detection. Bands were detected 
using an enhanced chemiluminescence kit (GE Healthcare, 
Saclay, France) and quantified using the densitometric 
analysis option in the Bio-Rad image acquisition system 
(Bio-Rad Laboratories, Marnes-la-Coquette, France). 
For lipid rafts disruption induced by surface cholesterol 
depletion, MCF-7 cells were treated with 5 mg/mL of 
Methyl-β-cyclodextrin (Sigma-Aldrich) for 24 h in 
complete culture medium.
Public breast cancer dataset analyses
Human breast cancer genome-wide expression 
profile datasets from patient sample series deposited 
for public access in a MIAME-compliant format were 
obtained through the Gene Expression Omnibus (GEO) 
database at the NCBI website [60], except for the Chin-
124 dataset (E-TABM-158), which was from EMBL-EBI 
ArrayExpress (www.ebi.ac.uk/arrayexpress). Full data on 
the profiling experiments and the patient cohort clinical 
data for all datasets are available at the GEO/EMBL-EBI 
sites through their GSE/E-TABM and PubMed PMID 
numbers, listed in Table 1 and its legend. CEL data were 
analyzed as described in [61]. Briefly, gene transcript levels 
from studies using Affymetrix arrays were determined 
from data image files using GeneChip operating software 
(MAS5.0 and GCOS1.0, from Affymetrix). Samples were 
scaled by setting the average intensity of the middle 96 % 
of all probe-set signals to a fixed value of 100 for every 
sample in the dataset, allowing comparisons between 
micro-arrays. The Servant-343 (GSE30682), Jonsdottir-94 
(GSE46563), and Wessels-178 (GSE34138) studies used 
Illumina arrays, and underwent custom processing and 
normalization as described on their GSE pages at the GEO 
site. The TCGA-528 study used a custom Agilent 244 K 
array, as described on http://tcga.cancer.gov/dataportal. 
The TranscriptView genomic analysis and visualization 
tool within R2 was used to verify that probe-sets had an 
anti-sense position in an exon of the gene (http://r2.amc.
nl > genome browser). The Affymetrix probe-sets selected 
for KCA3.1 (KCNN4 gene; 204401_at for Affymetrix 
arrays and ILMN_1709937 for Illumina arrays), and for 
TRPC1 (205802_at/205803_s_at and ILMN_1674380, 
respectively) meet these criteria and showed significant 
expression in > 25% of samples in each dataset. Analyses 
were performed using R2; a genomics analysis and 
visualization platform developed by Jan Koster in the 
Department of Oncogenomics at the Academic Medical 
Center – University of Amsterdam (http://r2.amc.nl).
statistical analysis 
Data are presented as means ± SE (n = number of 
individual measurements). Plots were produced using Igor 
Pro (by WaveMetrics, Lake Oswego, OR Inc.). Statistical 
analysis of the data was performed using ANOVA 
(Figures 1, 2 4 and 5) or paired t-tests (Figures 3 and 6) 
as appropriate. KCa3.1 mRNA expression correlation 
with breast cancer clinical and genetic features (Figure 7 
and Table 1) were determined using the non-parametric 
Kruskal-Wallis test, to prevent undue influence of non-
normally distributed data. KCa3.1 mRNA expression 
correlation with survival probability (Figure 8) was 
evaluated by Kaplan-Meier analysis using the log-rank 
test as described [62]. For all tests, differences were 
considered significant if p < 0.05.
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